<DOC>
	<DOCNO>NCT01584830</DOCNO>
	<brief_summary>The purpose study assess Regorafenib combination best supportive care slow tumor progression result increase survival patient metastatic colorectal cancer .</brief_summary>
	<brief_title>Asian Subjects With Metastatic Colorectal Cancer Treated With Regorafenib Placebo After Failure Standard Therapy</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Histological cytological documentation adenocarcinoma colon rectum . All histological type exclude . Subjects metastatic colorectal cancer ( CRC ) ( Stage IV ) . Subjects must fail least two line prior treatment . Progression within 3 month follow last administration approve standard therapy must include fluoropyrimidine , oxaliplatin irinotecan . Subjects treat oxaliplatin adjuvant setting progress within 6 month completion adjuvant therapy . Subjects progress 6 month completion oxaliplatin contain adjuvant treatment must retreat oxaliplatinbased therapy eligible . Subjects withdrawn standard treatment due unacceptable toxicity warrant discontinuation treatment preclude retreatment agent prior progression disease also allow study . Subjects may receive prior treatment Avastin ( bevacizumab ) and/or Erbitux ( cetuximab ) /Vectibix ( panitumumab ) ( KRAS WT ) Metastatic CRC subject must measurable non measurable disease accord Response Evaluation Criteria Solid Tumors ( RECIST ) criterion , version 1.1 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status 1 . Life expectancy least 3 month . Adequate bone marrow , liver renal function assess laboratory require protocol . Prior treatment Regorafenib . Previous concurrent cancer distinct primary site histology colorectal cancer within 5 year prior randomization EXCEPT curatively treat cervical cancer situ , nonmelanoma skin cancer superficial bladder tumor [ Ta ( noninvasive tumor ) , Tis ( carcinoma situ ) T1 ( tumor invades lamina propria ) ] . Extended field radiotherapy within 4 week limited field radiotherapy within 2 week prior randomization . Cardiological disease include Congestive heart failure , Unstable angina , Myocardial infarction , Cardiac arrhythmia require antiarrhythmic therapy . Uncontrolled hypertension . ( Systolic blood pressure 150 mmHg diastolic pressure 90 mmHg despite optimal medical management ) . Subjects phaeochromocytoma . Pleural effusion ascites cause respiratory compromise . Arterial venous thrombotic embolic event . Any history currently know brain metastasis . Interstitial lung disease ongoing sign symptoms time informed consent . Systemic anticancer therapy include cytotoxic therapy , signal transduction inhibitor , immunotherapy , hormonal therapy trial within 4 week .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Regorafenib</keyword>
	<keyword>Colorectal</keyword>
	<keyword>Metastatic</keyword>
</DOC>